Mark J. Donohue | Impax Laboratories, Inc. |
Paul M. Bisaro | Impax Laboratories, Inc. |
Bryan M. Reasons | Impax Laboratories, Inc. |
Douglas S. Boothe | Impax Laboratories, Inc. |
Marc Goodman | UBS Securities LLC |
David A. Amsellem | Piper Jaffray & Co. |
Gregg Gilbert | Deutsche Bank Securities, Inc. |
Dana Flanders | Goldman Sachs & Co. LLC |
Randall S. Stanicky | RBC Capital Markets LLC |
Ami Fadia | Leerink Partners LLC |
Elliot Wilbur | Raymond James & Associates, Inc. |
Andrew Finkelstein | Susquehanna Financial Group LLLP |
Louise Chen | Cantor Fitzgerald Securities |
Dewey Steadman | Canaccord Genuity, Inc. |
Gary Nachman | BMO Capital Markets (United States) |
Rohit Vanjani | Guggenheim Securities LLC |
Timothy Chiang | BTIG LLC |
Good morning. My name is Brandi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Impax Laboratories fourth quarter and full-year 2017 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session.